Janelle M Hoskins

UNVERIFIED PROFILE

Are you Janelle M Hoskins?   Register this Author

Register author

Janelle M Hoskins

Publications by authors named "Janelle M Hoskins"

Are you Janelle M Hoskins?   Register this Author

30Publications

-Reads

Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD.

Molecules 2017 Jan 15;22(1). Epub 2017 Jan 15.

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

View Article
January 2017

Accuracy of SNPs to predict risk of HLA alleles associated with drug-induced hypersensitivity events across racial groups.

Pharmacogenomics 2015 Jul 17;16(8):817-24. Epub 2015 Jun 17.

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, PR China.

View Article
July 2015

Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury.

Clin J Pain 2015 Jan;31(1):21-9

*Department of Surgery, University of North Carolina, Chapel Hill §Wake Forest Baptist Medical Center, Winston-Salem, NC †Washington Hospital Center, Washington, DC ‡Crozer Chester Medical Center, Upland, PA.

View Article
January 2015

Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcome.

PLoS One 2012 27;7(7):e41954. Epub 2012 Jul 27.

Division of Pharmacotherapy and Experimental Therapeutics, Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

View Article
January 2013

Assessing the utility of whole genome amplified DNA as a template for DMET Plus array.

Clin Chem Lab Med 2012 Feb 14;50(8):1329-34. Epub 2012 Feb 14.

UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC, USA.

View Article
February 2012

Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.

Pharmacogenomics 2012 Jan 23;13(1):113-21. Epub 2011 Nov 23.

University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, 3202 Kerr Hall, Chapel Hill, NC 27599-7569, USA.

View Article
January 2012

Copy number variants in pharmacogenetic genes.

Trends Mol Med 2011 May 8;17(5):244-51. Epub 2011 Mar 8.

UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Genetic Medicine Building, 120 Mason Farm Rd, Chapel Hill, NC 27599-7360, USA.

View Article
May 2011

The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.

Asia Pac J Clin Oncol 2011 Mar 30;7(1):65-74. Epub 2010 Dec 30.

Cancer Pharmacology Therapeutics Group Medical Oncology, St George and Sutherland Hospitals, Sydney, Australia.

View Article
March 2011

Irinotecan pharmacogenomics.

Pharmacogenomics 2010 Jul;11(7):1003-10

UNC Institute for Pharmacogenomics & Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.

View Article
July 2010

Pharmacogenetics of breast cancer therapies.

Breast 2009 Oct;18 Suppl 3:S59-63

UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, NC 27599, USA.

View Article
October 2009

CYP2D6 and tamoxifen: DNA matters in breast cancer.

Nat Rev Cancer 2009 Aug;9(8):576-86

UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, 27599, North Carolina, USA.

View Article
August 2009

Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.

Pharmacogenomics 2009 Jul;10(7):1139-46

UNC Institute for Pharmacogenomics & Individualized Therapy, University of North Carolina, Genetic Medicine Building, Chapel Hill, NC 27599-7360, USA.

View Article
July 2009

UGT1A and irinotecan toxicity: keeping it in the family.

J Clin Oncol 2009 May 13;27(15):2419-21. Epub 2009 Apr 13.

View Article
May 2009

Irinotecan pharmacogenetics: influence of pharmacodynamic genes.

Clin Cancer Res 2008 Mar;14(6):1788-96

Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.

View Article
March 2008

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.

Clin Cancer Res 2008 Feb;14(3):817-25

Department of Molecular Pharmacology, Sydney Cancer Centre, University of Sydney, Sydney, New South Wales, Australia.

View Article
February 2008

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

J Natl Cancer Inst 2007 Sep 28;99(17):1290-5. Epub 2007 Aug 28.

UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599-7360, USA.

View Article
September 2007

Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.

J Clin Oncol 2006 Jun 1;24(16):2448-55. Epub 2006 May 1.

Westmead Institute for Cancer Research Westmead Millennium Institute, Department of Translational Oncology, Westmead, Australia.

View Article
June 2006

Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer.

Clin Pharmacol Ther 2005 Jan;77(1):33-42

Westmead Institute for Cancer Research, Department of Nuclear Medicine, Westmead Hospital, University of Sydney, Camperdown, Australia.

View Article
January 2005

Effect of short-term morphine exposure on P-glycoprotein expression and activity in cancer cell lines.

Oncol Rep 2004 May;11(5):1091-5

Children's Cancer Institute of Australia for Medical Research, Randwick, Sydney, NSW 2031, Australia.

View Article
May 2004

Concordance between proguanil phenotype and CYP2C19 genotype in Chinese.

Eur J Clin Pharmacol 2003 Nov 12;59(8-9):611-4. Epub 2003 Sep 12.

Department of Clinical Pharmacology, Royal North Shore Hospital, NSW 2065, St. Leonards, Australia.

View Article
November 2003